<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 21, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144014</url>
  </required_header>
  <id_info>
    <org_study_id>V10153-2S-01</org_study_id>
    <nct_id>NCT00144014</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study in Acute Ischaemic Stroke</brief_title>
  <acronym>VASST</acronym>
  <official_title>A Phase II, Multi-centre, Two-part Study to Evaluate the Safety and Efficacy of Study Drug in Acute Ischaemic Stroke.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vernalis (R&amp;D) Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vernalis (R&amp;D) Ltd</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II study to evaluate the safety and efficacy of five dose levels of study drug in
      acute ischaemic stroke
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, dose escalation study where patients with acute ischaemic stroke will receive
      a single intravenous dose of study drug. There will be five dose levels with groups of 10
      patients in each. Escalation to higher doses will occur following review of safety data from
      the previous dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To establish the safety of five dose levels (1.0, 2.5, 5, 7.5 and 10 mg/kg)of V10153 in patients with acute ischaemic stroke.</measure>
    <time_frame>Ongoing</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare recanalisation rates across dose levels.</measure>
    <time_frame>Ongoing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare clinical outcome between treatments by NIHSS, Modified Rankin Scale and Barthel Index.</measure>
    <time_frame>Post-study completion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>V10153, 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single acute intravenous bolus dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V10153, 2.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single acute intravenous bolus dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V10153, 5.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single acute intravenous bolus dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V10153, 7.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single acute intravenous bolus dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V10153, 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single acute intravenous bolus dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V10153</intervention_name>
    <description>Single acute intravenous bolus dose up to 10 mg/kg</description>
    <arm_group_label>V10153, 1.0 mg/kg</arm_group_label>
    <arm_group_label>V10153, 2.5 mg/kg</arm_group_label>
    <arm_group_label>V10153, 5.0 mg/kg</arm_group_label>
    <arm_group_label>V10153, 7.5 mg/kg</arm_group_label>
    <arm_group_label>V10153, 10 mg/kg</arm_group_label>
    <other_name>Code Names: V10153, BB-10153</other_name>
    <other_name>CAS Registry Number: 931101-84-7</other_name>
    <other_name>Proposed INN: Troplasminogen alfa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Summary of Inclusion Criteria:

          1. Onset of new neurological signs of stroke within 3 to 9 hours of the time to
             initiation of treatment

          2. Aged 18 and above

          3. Provide consent

          4. Cerebral CT scan to show findings of early ischaemic changes consistent with the
             clinical diagnosis and an ASPECT score of between 5 and 10 inclusive.

          5. NIHSS score greater than 5 or less than or equal to 20.

        Summary of Exclusion Criteria:

          1. Coma

          2. Stroke with unknown time of onset

          3. Minor stroke symptoms and sings (&lt;6 points on the NIHSS) which are rapidly improving
             by the time of randomisation.

          4. Major stroke symptoms and signs (&gt;20 on the NIHSS)

          5. History of stroke in previous 6 weeks

          6. History of brain tumours

          7. CT scan results in an ASPECT score of &lt;5

          8. Haemorrhagic risk

          9. Abnormal laboratory values

         10. Positive urine pregnancy test, lactation or parturition within previous 30 days.

         11. Weight &gt;135 kg

         12. Uncontrolled hypertension.

         13. Raised blood glucose

         14. History of or current serious illness

         15. Participation in another clinical trial within 4 weeks of drug administration
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hill</last_name>
    <role>Principal Investigator</role>
    <affiliation>Foothills Hosptial</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stroke Centre, Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Stroke Network</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Medical Group of Diablo Valley</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Memorial Hospital</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradenton Research Centre</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Neurodiagnostic Centre</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital of Neuroscience Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Hospital</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Neurovascular Institue Stroke Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vascular Neurology, Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Medicine, Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMAS Memorial Medical Centre</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Hospital and Medical Centre</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washoe Stroke Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stroke Centre, Neurological Institute, Carolinas Medical Centre</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University South Carolina Hospitals and Clinics</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erlanger Health System</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Institute, The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Neuro-Ophthalmology, Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gordon &amp; Leslie Diamond Health Care Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Stroke Research, Vancouver Island Health Research Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>71 King Street West</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 4A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 0L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Charles LeMoyne</name>
      <address>
        <city>Quebec</city>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 4, 2016</lastchanged_date>
  <firstreceived_date>September 1, 2005</firstreceived_date>
  <firstreceived_results_disposition_date>May 4, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute</keyword>
  <keyword>Ischaemic</keyword>
  <keyword>Stroke</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
